Jewish 100, 2015: Rivka Carmi – Academia
Error: Contact form not found.
by Algemeiner Staff
Rivka Carmi
Doctor
Rivka Carmi is an innovative Israeli pediatrician and geneticist, who has served since 2006 as president of Ben-Gurion University of the Negev.
Her accolades are many; in 2015, she received an honorary Commander of the British Empire (CBE) in the name of Queen Elizabeth II. She was honored for her work to deepen scientific and academic relations between the United Kingdom and Israel.
Before she became the first woman president of a major Israeli university, Carmi’s research focused mainly on delineation of the clinical manifestations and molecular basis of genetic diseases in the Negev Arab-Bedouin population. Her work resulted in the identification of 12 new genes and the delineation of three new syndromes, one of which is known as the Carmi Syndrome.
New Nonprofit Publishing Company for Jewish, Israeli, Zionist Writers Welcomes Submissions
France Tightens Security Around Jewish Sites Ahead of High Holy Days Amid Rising Antisemitic Threats
‘Neo-Nazi’ Fighter Widely Condemned for Antisemitic Slur, Nazi Salutes After Beating Jewish Opponent
Iran’s Rial in Free Fall: How US Sanctions Are Reshaping Daily Life, Public Opinion for the Iranian People
Iran Warns US Against Israeli Attack on South Lebanon Ridge Held by Hezbollah, Sources Say
Syria Begins Destroying Assad-Era Chemical Weapons
Syria Is Off the Terror List, but Washington Still Has Leverage
As the Academic Year Starts, Antisemitism Comes to K-12 Schools in Addition to Universities
Abbas Rival Mohammed Dahlan’s Emerging Alliance Deserves Scrutiny
Who Will Pay the Price for the UK’s Potential Settlement Trade Ban?






Jewish Groups Launch First-of-Its-Kind European Center for Medical Training, Certification of Mohels
Germany Successfully Tests Israeli Ballistic Missile, Officials Say
Trump Says Renewed US Campaign Against Iran Won’t Last Long After Biggest Exchange of Fire Since July
Abbas Rival Mohammed Dahlan’s Emerging Alliance Deserves Scrutiny
Who Will Pay the Price for the UK’s Potential Settlement Trade Ban?



